

# The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus

Isa Murrell<sup>1</sup>, Carmen Bedford<sup>1</sup>, Kristin Ladell<sup>1</sup>, Kelly Miners<sup>1</sup>, David Price<sup>2</sup>, Peter Tomasec<sup>1</sup>, Gavin Wilkinson<sup>3</sup>, Richard J Stanton<sup>1</sup>

<sup>1</sup>Cardiff University, <sup>2</sup>Cardiff University School of Medicine, <sup>3</sup>Cardiff University, School of Medicine

Submitted to Proceedings of the National Academy of Sciences of the United States of America

**Human cytomegalovirus (HCMV) strains that have been passaged *in vitro* rapidly acquire mutations that impact viral growth. These laboratory-adapted strains of HCMV generally exhibit restricted tropism, produce high levels of cell-free virus and develop susceptibility to natural killer cells. To permit experimentation with a virus that retained the phenotype of clinical virus, we reconstructed a wild-type (wt) HCMV genome using bacterial artificial chromosome technology. Like clinical virus, this genome proved to be unstable in cell culture, however propagation of intact virus was achieved by placing the RL13 and UL128 genes under conditional expression. In this study, we show that wt-HCMV produces extremely low titers of cell-free virus but can efficiently infect fibroblasts, epithelial, monocyte-derived dendritic and Langerhans cells via direct cell-cell transmission. This process of cell-cell transfer required the UL128 locus, but not the RL13 gene, and was significantly less vulnerable to the disruptive effects of interferon, cellular restriction factors and neutralizing antibodies compared with cell-free entry. Resistance to neutralizing antibodies was dependent on high-level expression of the pentameric gH/gL/gpUL128–131A complex, a feature of wt but not passaged strains of HCMV.**

Virology | Immune evasion | herpesvirus | HCMV | cell-cell spread

Human cytomegalovirus is a major cause of morbidity and mortality in the immunocompromised, and the leading infectious cause of congenital malformation. As a result, a vaccine has been designated of the highest priority. However, basic studies of clinically relevant isolates that inform our understanding of the disease process are limited, due to the rapid accumulation of genetic mutations during *in vitro* passage of HCMV. The same three genetic sites are reproducibly affected: the RL13 gene, the UL128 locus (UL128L), which comprises UL128, UL30 and UL131A, and the ~15kb  $U_L/b'$  gene region (1). Deletions in the  $U_L/b'$  region can affect tropism (UL148 (2)), latency (UL136 and UL138 (3–7)) and resistance to NK cells (UL141 (8–10), UL142 (11, 12) and UL135 (13)). Disabling mutations in RL13 and UL128L independently contribute to the release of high-titer cell-free virus, while loss of UL128L restricts virus entry to fibroblasts alone by preventing assembly of a pentameric glycoprotein complex (gH/gL/pUL128/pUL130/pUL131A) in the virion envelope (1, 14, 15).

The rapid selection of mutations is a major obstacle to the propagation of genetically intact 'clinical' strains of HCMV, which in turn has led to significant gaps in our understanding of the affiliated disease processes (16). In particular, HCMV is largely cell-associated *in vivo* (17), and clinical isolates exhibit a similar phenotype *in vitro* (17, 18), yet most studies in the field are based on laboratory strains that produce high titers of cell-free virus (19). As a consequence, little is known about the fundamental processes involved in the infectious spread of cell-associated HCMV.

In this study, we used a system that permits *in vitro* experimentation with a genetically complete virus that retains the cell-

associated phenotype displayed by clinical isolates of HCMV. Our data show that cell-cell transfer differs both qualitatively and quantitatively from cell-free infection, enabling the virus to overcome intrinsic cellular restriction factors, interferon-induced antiviral factors and antibody-mediated neutralization. Moreover, the ability of wild-type (wt)-HCMV to spread via the cell-cell route below the radar of humoral immune defences can be attributed to high-level expression of the pentameric complex. Collectively, these findings provide new insights into the mechanisms that facilitate the *in vivo* persistence of HCMV.

## RESULTS

### Cell-cell spread is more efficient than cell-free infection

To recapitulate cell-cell spread of wt-HCMV *in vitro*, the complete strain Merlin genome was captured in a bacterial artificial chromosome (BAC) (14). The virus was then propagated *in vitro* with RL13 and UL128-131A under the control of a tetracycline repressor (tetR). This strategy prevented the acquisition of mutations in culture (20). The pentameric complex and gpRL13 were subsequently restored to virions during a single infectious cycle in fibroblasts lacking tetR (Fig. 1A). Extremely low quantities of cell-free virus were produced under these conditions, akin to clinical isolates, with peak titers below 70 PFU/ml, which equates to 1 PFU per 1,750 infected cells (Fig. 1B).


As this extremely low yield of cell-free virions would not be sufficient to sustain the infection, we reasoned that wt-Merlin must be transmitted via direct cell-cell spread. Initial experiments

### Significance

**Strains of human cytomegalovirus (HCMV) that have been passaged in the laboratory fail to recapitulate the phenotypic characteristics of *ex vivo* isolates due to the rapid acquisition of genetic mutations. In particular, clinical viruses spread via direct cell-cell contact, while passaged strains spread via diffusion of cell-free virions. We developed a method that enables *in vitro* propagation of genetically intact HCMV. Using this system, we now report that cell-cell transmission of wild-type HCMV is not only highly efficient, but also enables the virus to overcome key innate and adaptive immune defences. These findings inform our understanding of viral persistence and validate a new approach to experimentation that may facilitate the design of improved prophylactic and therapeutic interventions against HCMV.**

### Reserved for Publication Footnotes


137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204



**Fig. 1. Characterization of cell-cell infection.** (A) Diagrammatic representation of the method used to grow wild-type Merlin *in vitro* without risk of mutation. (B) HFFFs were infected with variants of the Merlin BAC containing mutations in both UL128 and RL13, wt (tet-regulated) UL128, or wt (tet-regulated) UL128 and wt (tet-regulated) RL13 (MOI = 5). Virus was titrated from supernatants or sonicated cell preparations. Cell-released virus (CRV) and cell-associated virus (CAV) represent the total infectivity obtained from cells or supernatant, respectively, over the course of the experiment. (C) HFFFs infected with Merlin expressing IE2-GFP (MOI = 5; 72 h post-infection) were stained with DDAO, then co-cultured with either DCs or RPE-1 cells at the indicated ratios. Samples were analyzed by flow cytometry after a further 72 h to determine the percentage of infected DCs or RPE-1 cells (DDAO<sup>+</sup>/GFP<sup>+</sup>). Representative data are shown. (D) DCs were co-cultured with Merlin-infected HFFFs (MOI = 5; 72 h post-infection) for the indicated time periods. Non-adherent cells were then removed and incubated alone prior to flow cytometric analysis 72 h after the start of co-culture. In some experiments, a transwell was placed between the DCs and HFFFs, and the cultures were incubated for 72 h. Alternatively, DCs were infected via the cell-free route using virus harvested from Merlin-infected HFFF supernatants and incubated in isolation for 72 h. Virus lacking UL128-131A expression (UL128<sup>-</sup>) was used in one well. Representative data are shown.

were therefore performed with a virus (hereon termed simply 'Merlin') lacking RL13, which complicates the production of cell-free virus (14), to compare the different modes of infection. Infected human fetal foreskin fibroblasts (HFFFs; Fig 1A) were pre-stained with DDAO and mixed with uninfected cells. Subsequent infection was then identified via GFP expression linked to the viral IE-2 gene (Supplemental Fig. 1A). Both adherent epithelial (RPE-1) and non-adherent dendritic cells (DCs) were readily infected in these assays (Fig. 1C). Notably, the donor-recipient cell ratio strongly influenced the efficiency of infection in co-cultures with RPE-1 cells, while little effect was observed in co-cultures with DCs.

To determine the kinetics of cell-cell transfer, DCs were removed from co-culture at different time points and incubated in isolation for 72 h (Fig. 1D). For comparison with cell-free infection, DCs were incubated for the same length of time with supernatant collected from infected HFFFs over a period of 72 h. Alternatively, transwells were used to separate DCs from infected HFFFs. In both cases, the DCs remained uninfected, indicating that cell-cell contact is required for infection with Merlin. In contrast, infected DCs were readily detected within 4 h of co-culture and accumulated progressively with time. After 24 h, one infected DC was detected for every infected HFFF, making cell-cell transfer of Merlin > 1,750-fold more efficient than cell-free infection. Importantly, virus lacking the pentameric complex was unable to spread into DCs, and provided an additional control to verify that only newly infected DCs were counted in these analyses. To verify that GFP expression was linked to productive




**Fig. 2. Cell-cell spread is resistant to neutralizing antibodies.** (A,B) Cell-free Merlin-GFP was incubated for 1 h with specific antibodies (light blue) against gB (C23; 3.6 µg/ml) or UL130 and UL131A (a 1:50 dilution of a 50:50 mixture of polyclonal rabbit sera raised against peptides from UL130 and UL131A), Cytotect (purple) or serum from donors testing seronegative (white) or seropositive (black) for HCMV (1:50). HFFFs (A) or ARPE-19 cells (B) were then infected for 2 h, overlaid and incubated for 2 weeks. Infected cells were quantified by plaque assay. Percent neutralization was calculated relative to the negative control (no antibody). (C-E) HFFFs were infected with Merlin-GFP (MOI = 5), then stained with DDAO after 72 h and incubated with HFFFs (C), ARPE-19 cells (D) or DCs (E) in the presence of antibodies or sera as described in (A,B). Infected cells were quantified by flow cytometry 48 h after the start of co-culture. Percent neutralization was calculated relative to the negative control (no antibody). (F) HFFFs were infected with Merlin-GFP (MOI = 5), then stained with DDAO after 72 h and incubated with HFFFs, ARPE-19 cells or DCs in the presence of the indicated concentrations of Cytotect. Infected cells were quantified by flow cytometry 48 h after the start of co-culture. (G) Cell-free Merlin was incubated with the indicated concentrations of Cytotect for 30 min. HFFFs, ARPE-19 cells or DCs were then infected for 2 h. After a further 24 h, cells were fixed and stained for IE-1. Infected cells were quantified by flow cytometry. Percent neutralization was calculated relative to the negative control (no Cytotect). (H) The concentration of Cytotect that inhibited infection by 50% was calculated from panels F and G.

infection, GFP<sup>+</sup> cells were first sorted to purity using flow cytometry (Supplemental Fig. 1B). Subsequent imaging revealed that the GFP signal was localized to the nucleus, consistent with *de*


205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272

273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340



**Fig. 3. Levels of the pentameric complex correlate with resistance to neutralizing antibodies.** (A) ARPE-19 cells were infected at 60 PFU/well with either TB40-BAC4 or Merlin and incubated for 21 days in the presence of seronegative or seropositive sera (1:50). Cells were imaged after fixing and staining for IE-1. (B, C) ARPE-19 cells were infected with either TB40-BAC4 (B) or Merlin (C) and incubated for 21 days in the presence of Cytotect (purple) or seronegative (white) or seropositive (black) sera (1:50). Plaque size was measured after fixing and staining for IE-1. (D) ARPE-19 cells were infected with 60 PFU/well of either TB40-BAC4, Merlin or Merlin-UL128<sup>G2T</sup> and incubated for 21 days in the presence of the indicated concentrations of Cytotect. Plaque size was measured after fixing and staining for IE-1. Percent inhibition was calculated relative to the negative control (no Cytotect). (E) Cell-free Merlin, Merlin-UL128<sup>G2T</sup> or TB40-BAC4 were incubated with the indicated concentrations of Cytotect for 30 min. ARPE-19 cells were then infected for 2 h and incubated for a further 24 h. Infected cells were counted after fixing and staining for IE-1. Percent neutralization was calculated relative to the negative control (no Cytotect). (F) The concentration of Cytotect that inhibited plaque formation or cell-free infection by 50% was calculated from panels D and E. (G) Cell-free Merlin, Merlin-UL128<sup>G2T</sup> or TB40-BAC4 were incubated with the indicated concentrations of Cytotect for 30 min. HFFFs were then infected for 2 h and incubated for a further 24 h. Infected cells were counted after fixing and staining for IE-1. Percent neutralization was calculated relative to the negative control (no Cytotect). Error bars represent SEM.

*novo* expression of the IE-2-GFP fusion protein (Supplemental Fig. 1C). In addition, virus was readily transferred back to HFFFs in co-cultures with flow-purified DCs (Supplemental Fig. 1D).



**Fig. 4. Cell-cell spread in Langerhans cells is highly efficient and resistant to IFN $\alpha$ .** (A) Immature DCs or LCs were incubated for 24 h with cell-free preparations of TB40-BAC4 or Merlin. The percentage of infected cells was calculated by microscopy after staining with a mouse anti-IE-1 antibody and DAPI. (B) DCs or LCs were incubated for 4 h or 48 h at a 1:1 ratio with Merlin-GFP-infected HFFFs (MOI = 5; 72 h post-infection) or cell-free Merlin-GFP. Non-adherent cells were then removed and incubated alone prior to flow cytometric analysis 72 h after the start of co-culture or cell-free infection. (C) DCs or LCs were cultured for 24 h in the presence or absence of IFN $\alpha$ , then incubated for 4 h or 48 h with Merlin-GFP-infected HFFFs (MOI = 5; 72 h post-infection) or cell-free Merlin-GFP. Non-adherent cells were then removed and incubated alone prior to flow cytometric analysis 72 h after the start of co-culture or cell-free infection. Assays were performed in quadruplicate. \*\* P < 0.01, \*\*\*\* P < 0.0001 (ANOVA). Error bars represent SEM.

Collectively, these data show that UL128L expression correlates with cell association during the replicative cycle of a HCMV isolate containing a clinical genome, and facilitates efficient cell-cell transmission into epithelial and myeloid cells.

**Cell-cell spread is resistant to neutralizing antibodies**

Many current vaccine strategies are designed to induce a neutralizing antibody response (21-27). However, it is unclear whether the transmission of HCMV is sensitive or resistant to neutralization, potentially because many studies have used viruses that spread efficiently via the cell-free route (19, 28-36). To determine the neutralization sensitivity of Merlin, we tested a panel of antibody preparations. Cell-free infection of HFFFs and ARPE-19 epithelial cells was inhibited in all cases (Fig.2A,B), while direct cell-cell transmission into HFFFs, ARPE-19 epithelial cells and DCs was largely unaffected (Fig.2C-E).

Cytotect is a clinical grade product containing high neutralizing antibody titers against HCMV. In a recent clinical trial, this formulation was used at a concentration of 100 mg/kg (37). Based on data from other intravenous immunoglobulin preparations, this could increase serum IgG levels by up to 2 mg/ml (38). To test the efficiency of cell-cell transfer under clinically relevant conditions, HFFFs, ARPE-19 epithelial cells or DCs were infected via the cell-cell route in the presence of Cytotect concentrations as high as 10mg/ml (Fig. 2F). Cell-cell transfer into ARPE-19 epithelial cells and DCs was inhibited by 50% at concentrations of 6-8mg/ml, while cell-cell transfer into HFFFs was inhibited by < 50% at a concentration of 10 mg/ml. Similarly, only weak inhibition of cell-cell transfer of virus from flow-purified DCs back into HFFFs or ARPE-19 epithelial cells was observed at maximal concentrations of Cytotect (Supplemental Fig. 2); at

341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408



409 these high concentrations, it is even possible that the effects  
410 observed are non-specific, rather than being due to anti-CMV  
411 antibodies. In contrast, cell-free infection with the same virus was  
412 inhibited by 50% at concentrations < 50 µg/ml (HFFFs and DCs)  
413 or < 15 µg/ml (ARPE-19 epithelial cells) (Fig. 2G,H).

414 To provide comparisons with cell-free infection, experiments  
415 thus far had been performed with virus lacking RL13. Identical  
416 assays were therefore performed using a virus expressing the  
417 complete wt-HCMV proteome (Merlin-RL13<sup>+</sup>). No consistent  
418 differences in the efficiency of cell-cell transfer were observed be-  
419 tween Merlin and Merlin-RL13<sup>+</sup>, and both viruses were equally  
420 resistant to the inhibitory effects of Cytotect (Supplement Fig.3).

421 Thus, cell-cell spread of Merlin is only inhibited at extremely  
422 high antibody concentrations, while cell-free infection is > 400-  
423 fold more susceptible to neutralization.

#### 424 **Resistance to neutralizing antibodies is dependent on high** 425 **levels of the pentameric complex**

426 Our findings that cell-cell spread into epithelial cells is resis-  
427 tant to neutralising antibodies is in direct contrast with a large  
428 number of studies in which focus formation in epithelial cells  
429 was found to be highly sensitive to neutralizing antibodies (28,  
430 30, 32-34, 39). To resolve this discrepancy, we performed focus  
431 expansion assays using the TB40-BAC4 strain of HCMV. TB40-  
432 BAC4 is exceptional in retaining the capacity to infect endothe-  
433 lial, epithelial and myeloid cells following *in vitro* culture, and has  
434 been widely used for these types of study. Focal spread of TB40-  
435 BAC4 was highly sensitive to neutralization (Fig. 3A,B), while  
436 minimal inhibition was observed in parallel assays with Merlin  
437 (Fig. 3A,C). These findings were confirmed in similar experi-  
438 ments with higher concentrations of Cytotect, which revealed that  
439 Merlin was almost 600-fold more resistant to inhibition compared  
440 with TB40-BAC (Fig. 3D).

441 In common with most passaged strains of HCMV, TB40-  
442 BAC4 produces high titers of cell-free virus and incorporates  
443 reduced levels of gpUL128–131A in the virion, a characteristic  
444 partially endowed by a G>T nucleotide substitution in one of the  
445 UL128 introns (19). Mutation of the same nucleotide in the Mer-  
446 lin strain (Merlin-UL128<sup>G>T</sup>) reduces both cell-associated and  
447 virion-associated expression of the UL128 protein, such that it  
448 is intermediate between TB40-BAC4 and Merlin (Supplemental  
449 Fig. 4)(19). In line with UL128 expression levels, focal spread  
450 of Merlin-UL128<sup>G>T</sup> displayed an intermediate susceptibility to  
451 inhibition compared with Merlin and TB40-BAC4 (Fig. 3D).  
452 The same phenomenon was observed in assays with cell-free  
453 viruses (Fig. 3E), although the differences between strains were  
454 less pronounced (Fig. 3F). In contrast, this pattern was reversed  
455 in cell-free neutralization studies with HFFFs (Fig. 3G). These  
456 differences presumably reflect the fact that entry into fibroblasts  
457 is dependent on the gH/gL/gO complex. Viruses with reduced  
458 levels of gpUL128–131A (19) typically express greater amounts  
459 of gH/gL/gO (40) because gO and gpUL128–131A compete for  
460 binding to gL (41).

461 Thus, efficient expression of gpUL128–131A, a feature  
462 unique to strains containing a clinical genome (19), renders cell-  
463 cell spread highly resistant to humoral immunity, and cell-free  
464 entry partially resistant to antibodies that neutralise epithelial cell  
465 entry.

#### 466 **Cell-cell spread is resistant to intrinsic LC restriction factors**

467 In further experiments, we investigated whether cell-cell  
468 transfer might differ in other ways from cell-free transmis-  
469 sion. Langerhans cells (LCs) are specialized tissue-resident DCs  
470 thought to play a key role in the early stages of natural infection  
471 with HCMV (42). *In vitro*, immature DCs are readily infected via  
472 the cell-free route, whereas immature LCs are not (43, 44). This  
473 dichotomy was recapitulated with Merlin (Fig. 4A). In contrast,  
474 much greater numbers of immature LCs were infected via the  
475 cell-cell route over an equivalent period of time (Fig. 4B). Similar

476 patterns were observed, but with even higher infection frequen-  
477 cies, in longer term assays. Thus, not only were LCs more readily  
478 infected when using the cell-cell route, but the absolute number of  
479 infected cells that it was possible to achieve using cell-cell spread  
480 was much higher than that achieved by cell-free spread.

481 To ensure these differences were not dependent on the  
482 infected-cell secretome, we repeated the co-culture experiment  
483 with a transwell between TB40-BAC4-infected HFFFs and unin-  
484 fected DCs or LCs (Supplemental Fig. 5A). Alternatively, DCs  
485 or LCs were removed from the transwell after incubation for 72  
486 h over Merlin-infected HFFFs and exposed to cell-free Merlin  
487 (Supplemental Fig. 5B). In both cases, LCs remained significantly  
488 more resistant to infection compared with DCs.

489 Immature LCs are therefore significantly more susceptible to  
490 cell-cell infection relative to cell-free infection, consistent with  
491 greater intrinsic restriction of the free virion life cycle.

#### 492 **Cell-cell spread is resistant to interferon-induced antiviral** 493 **factors**

494 To extend this line of inquiry, we investigated the antiviral  
495 effect of interferon (IFN)α. In these experiments, DCs or LCs  
496 were treated with IFNα, then infected either via co-culture or  
497 by exposure to cell-free virus (Fig. 4C). Cell-free infection of  
498 both DCs and LCs was abrogated in the presence of IFNα. Com-  
499 parable results were obtained with virus infections performed  
500 with transwell membranes placed between infected HFFFs and  
501 uninfected DCs or LCs, indicating that these differences were not  
502 due to exposure to the infected cell secretome (Supplemental Fig.  
503 5C). In contrast, cell-cell transmission was inhibited only mod-  
504 erately by IFNα, even after 48 h. Similarly, cell-free infection of  
505 HFFFs was suppressed by IFNα, while cell-cell transfer between  
506 HFFFs (Supplemental Fig 5D), or from Merlin-infected DCs or  
507 LCs into uninfected HFFFs or ARPE-19 cells (Supplemental Fig.  
508 5E) was only minimally affected by IFNα.

509 Accordingly, cell-cell transfer is more resistant to innate im-  
510 munity compared with cell-free entry across a range of cell types.  
511 It is also notable that RL13 expression did not influence the  
512 susceptibility of this process to the antiviral effects of IFNα or  
513 the intrinsic restrictive properties of LCs (Supplemental Fig. 5F).

514 In sum, the findings reported here demonstrate that virus  
515 expressing the complete HCMV proteome spreads efficiently via  
516 the cell-cell route, a mode of propagation that confers resistance  
517 to multiple arms of the immune system.

## 518 **DISCUSSION**

519 The data presented here show that a genetically defined and  
520 clinically relevant strain of HCMV can infect a wide range of cell  
521 types via a process of direct transfer that differs qualitatively from  
522 cell-free entry and likely predominates *in vivo*. Previous studies  
523 have been limited to strains capable of cell-free transmission,  
524 such as FIX and TB40-BAC4, which incorporate mutations that  
525 reduce expression of the pentameric glycoprotein complex (19).  
526 However, clinical isolates are almost entirely cell-associated *in*  
527 *vitro* (18, 45), and the majority of virus is cell-associated *in*  
528 *vitro* (17). Moreover, cell-cell spread is essential for viral replication  
529 in animal models of CMV infection (46). Despite these fundamental  
530 observations, remarkably little is known about the physiological  
531 mechanism of cell-cell transfer. It is established that soluble  
532 proteins can be transmitted between infected cells (47), and  
533 that small fusion events can occur between infected endothe-  
534 lial cells and polymorphonuclear leukocytes (48). In addition,  
535 virus lacking UL99, an essential tegument protein required for  
536 free virion formation, can still spread via the cell-cell route in  
537 fibroblasts (49). Nonetheless, polymorphonuclear leukocytes are  
538 not productively infected, and virus lacking UL99 spreads very  
539 inefficiently compared with wt-HCMV. These studies also relied  
540 on virus strains that do not express the complete wt-HCMV  
541 proteome (1, 14, 16, 19). In contrast, our experiments with fully  
542  
543  
544

reconstituted strain Merlin allowed us to demonstrate that high levels of gpUL128–131A drive efficient cell-cell transmission and confer resistance to innate and adaptive immune defences.

These results will need to be validated using other strains of HCMV, since it is possible that there is strain-strain variation (32). This will require the construction of additional BACs containing genomes that match original clinical isolates, and contain tet operators upstream of UL128L and RL13 (14). Nonetheless, it seems likely that the pentameric complex is normally expressed at high levels *in vivo* given that clinical isolates grow in a cell-associated manner akin to Merlin and rapidly acquire similar ablatively mutations in UL128L *in vitro* (1), and that passaged strains with intact UL128L express lower levels of the protein due to acquired mutations (19). It remains unclear whether the observed effects on cell-cell transfer arise from virion- or cell-associated membrane expression of the pentameric complex, both of which are reduced by the G>T mutation used in this work. Previous studies have shown that HCMV forms syncytia in ARPE-19 and fibroblast cells, and that this can be inhibited by neutralizing antibodies (50, 51). These observations suggest a functional role for membrane-associated glycoproteins. However, relatively few syncytia were observed with TB40-BAC4, and very few syncytia were observed with Merlin or the Merlin-UL128<sup>G>T</sup> mutant.

Cell-cell spread has been particularly well studied in the context of retroviruses. Akin to HCMV, these viruses propagate significantly more efficiently via direct transfer compared with the cell-free route (52–54), and better overcome specific restriction factors and innate immune responses in the process (55–57). However, these similarities do not necessarily reflect common mechanisms of viral spread (58, 59). For example, cell-cell transfer of HIV can be inhibited by many different neutralizing antibodies (60–62), and although it is more resistant than cell-free infection with some antibodies (60, 63–67), the differences are significantly lower than the 400-fold observed for Merlin; the resistance of Merlin to all but the highest concentrations of neutralizing antibodies potentially indicates a qualitatively distinct mode of transmission. The data presented here also have substantial implications for the control of HCMV *in vivo*. During natural infection, LCs in the oral epithelium are most likely the first antigen-presenting cells to encounter HCMV (42). Immature LCs are resistant to infection via the cell-free route (44, 68), and it has been suggested that this potential bottleneck could feasibly be exploited to interrupt transmission (42). The propensity of wt-HCMV to spread via the cell-cell route would undermine any such efforts. In addition, cell-cell spread enhances the kinetics of viral infection (52, 69, 70) and enables drug resistance to develop more quickly in the setting of HIV (71, 72). These phenotypes can be attributed to the fact that multiple virions are delivered per cell during a cell-cell transmission event (71, 73). It remains to be determined whether the same is true for HCMV.

It will be interesting to determine whether antibodies capable of suppressing cell-cell spread are also effective at neutralising

cell-free virus. Nevertheless, the concentrations of IgG required to inhibit cell-cell transmission of Merlin may be difficult to achieve *in vivo* (38). This observation has profound ramifications for the development of therapeutic interventions, especially as current vaccine studies are focused on neutralizing antibodies (21–27). Several of these antibodies are considerably more potent than Cytotect when measured using cell-free passaged HCMV (21, 22, 33), raising the possibility that they could have efficacy against cell-cell spread of clinical virus. However, until they are tested against virus expressing the wildtype HCMV proteome, it is not possible to determine whether potent inhibition of cell-free infection correlates with inhibition of cell-cell spread, or whether inhibition of cell-cell spread is simply dependent upon antibody concentration. These antibodies may of course have efficacy *in vivo* by inhibiting initial cell-free infection from body fluids, yet our data suggests that once an initial infection has occurred, they may be less effective at preventing intra-host spread. Similarly, in both congenital infection and transplantation, where virus spread to the fetus/transplant recipient may conceivably occur by cell-cell spread, such antibodies may be less effective. It is notable in this context that studies of the role of neutralising antibodies *in vivo* are somewhat mixed; studies have documented an inverse correlation between neutralization titers and intrauterine transmission (74–77), and virus-specific antibodies have been shown to confer a degree of protection in animal models (78, 79) and in a trial in transplant patients (80). Yet the administration of polyclonal human IgG containing high titers of neutralizing antibodies failed to prevent congenital infection in a randomized clinical trial (37), and although anti-gB antibody titres correlated with protection in a vaccine study of transplant recipients, neutralising titres did not (81).

Collectively, our data highlight the importance of testing genetically defined viruses that accurately represent the causative agent of disease and provide evidence to suggest that neutralizing antibodies may only limit intra-host spread if present at very high concentrations. A successful vaccine may therefore need to also stimulate cytotoxic responses to eliminate cells that are already infected with HCMV (82).

## MATERIALS AND METHODS

### Co-culture

Infected HFFFs were washed prior to co-culture, incubated for 15 min with 222 ng/ml CellTrace Far Red (DDAO-SE; Invitrogen) in PBS, washed again and resuspended in regular growth medium. For co-culture with adherent cells (HFFFs, ARPE-19), infected HFFFs were trypsinized and overlaid on targets 3–7 days post-infection. For co-culture with non-adherent cells (DCs or LCs), targets were added directly to infected HFFFs 3–4 days post-infection. Non-adherent targets were washed off at various time points during co-culture. In all cases, cells were maintained for 72 h to allow expression of IE2-GFP. For analysis, cells were harvested (if non-adherent) or trypsinized (if adherent), stained with Fixable Viability 570 (BD), then either fixed in 2% paraformaldehyde and acquired using an Accuri C6 cytometer (BD) or acquired directly without fixation using a FACSAria II cytometer (BD). Informed consent was obtained from all volunteer blood donors, and experiments were approved by Cardiff University Research Ethics Committee

1. Dargan DJ, et al. (2010) Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. *J Gen Virol* 91(Pt 6):1535–1546.
2. Li G, Nguyen CC, Ryckman BJ, Britt WJ, & Kamil JP (2015) A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism. *Proc Natl Acad Sci U S A* 112(14):4471–4476.
3. Goodrum F, Reeves M, Sinclair J, High K, & Shenk T (2007) Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection *in vitro*. *Blood* 110(3):937–945.
4. Li G, et al. (2014) An epistatic relationship between the viral protein kinase UL97 and the UL133–UL138 latency locus during the human cytomegalovirus lytic cycle. *J Virol* 88(11):6047–6060.
5. Umashankar M, et al. (2014) Antagonistic determinants controlling replicative and latent states of human cytomegalovirus infection. *J Virol* 88(11):5987–6002.
6. Lee SH, Albright ER, Lee JH, Jacobs D, & Kalejta RF (2015) Cellular defense against latent colonization foiled by human cytomegalovirus UL138 protein. *Sci Adv* 1(10):e1501164.
7. Caviness K, et al. (2016) Complex Interplay of the UL136 Isoforms Balances Cytomegalovirus Replication and Latency. *MBio* 7(2):e01986.

8. Smith W, et al. (2013) Human Cytomegalovirus Glycoprotein UL141 Targets the TRAIL Death Receptors to Thwart Host Innate Antiviral Defenses. *Cell Host Microbe* 13(3):324–335.
9. Prod'homme V, et al. (2010) Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. *J Gen Virol* 91(Pt 8):2034–2039.
10. Tomasec P, et al. (2005) Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. *Nat Immunol* 6(2):181–188.
11. Chalupny NJ, Rein-Weston A, Dosch S, & Cosman D (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. *Biochem Biophys Res Commun* 346(1):175–181.
12. Wills MR, et al. (2005) Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. *J Immunol* 175(11):7457–7465.
13. Stanton RJ, et al. (2014) HCMV pUL135 Remodels the Actin Cytoskeleton to Impair Immune Recognition of Infected Cells. *Cell Host Microbe* 16(2):201–214.
14. Stanton RJ, et al. (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. *J Clin Invest* 120(9):3191–3208.
15. Revello MG & Gerna G (2010) Human cytomegalovirus tropism for endothelial/epithelial

681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748

cells: scientific background and clinical implications. *Reviews in medical virology* 20(3):136-155.

16. Wilkinson GW, et al. (2015) Human cytomegalovirus: taking the strain. *Med Microbiol Immunol* 204(3):273-284.

17. Ziemann M & Hennig H (2014) Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy? *Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft für Transfusionsmedizin und Immunhamatologie* 41(1):40-44.

18. Waldman WJ, Sneddon JM, Stephens RE, & Roberts WH (1989) Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells. *J Med Virol* 28(4):223-230.

19. Murrell I, et al. (2013) Impact of Sequence Variation in the UL128 Locus on Production of Human Cytomegalovirus in Fibroblast and Epithelial Cells. *J Virol* 87(19):10489-10500.

20. Murrell I, et al. (2016) Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro. *J Virol* 90(8):3929-3943.

21. Macagno A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. *J Virol* 84(2):1005-1013.

22. Freed DC, et al. (2013) Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. *Proc Natl Acad Sci U S A* 110(51):E4997-5005.

23. Wen Y, et al. (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. *Vaccine* 32(30):3796-3804.

24. Wussow F, et al. (2014) Human Cytomegalovirus Vaccine Based on the Epitope gH/gL Pentamer Complex. *PLoS Pathog* 10(11):e1004524.

25. Wussow F, et al. (2013) A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. *J Virol* 87(3):1322-1332.

26. Kabanova A, et al. (2014) Antibody-driven design of a human cytomegalovirus gH/gLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. *Proc Natl Acad Sci U S A* 111(50):17965-17970.

27. Fu TM, et al. (2012) Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. *Vaccine* 30(52):7469-7474.

28. Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, & Adler B (2011) HCMV Spread and Cell Tropism are Determined by Distinct Virus Populations. *PLoS Pathog* 7(1):e1001256.

29. Jiang XJ, et al. (2008) UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. *J Virol* 82(6):2802-2812.

30. Frenzel K, et al. (2012) Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines. *Med Microbiol Immunol* 201(3):277-286.

31. Navarro D, et al. (1993) Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. *Virology* 197(1):143-158.

32. Cui X, Lee R, Adler SP, & McVoy MA (2013) Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. *J Virol Methods* 192(1-2):44-50.

33. Kauvar LM, et al. (2015) A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. *Antimicrob Agents Chemother* 59(3):1558-1568.

34. Jiang XJ, et al. (2011) UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies. *Arch Virol* 156(12):2145-2155.

35. Sinzger C, et al. (2007) Effect of serum and CTL on focal growth of human cytomegalovirus. *J Clin Virol* 38(2):112-119.

36. Jacob CL, et al. (2013) Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. *Virology* 444(1-2):140-147.

37. Revello MG, et al. (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. *N Engl J Med* 370(14):1316-1326.

38. Thurmman PA, Sonnenburg-Chatzopoulos C, & Lissner R (1995) Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. *Eur J Clin Pharmacol* 49(3):237-242.

39. Subramanian N, Wu Z, & Mertens TM (2016) Phenotypic characterization of human cytomegalovirus strains in cell cultures based on their transmission kinetics. *J Gen Virol* 97(9):2376-2386.

40. Zhou M, Yu Q, Wechsler A, & Ryckman BJ (2013) Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. *J Virol* 87(17):9680-9690.

41. Ciferri C, et al. (2015) Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. *Proc Natl Acad Sci U S A* 112(6):1767-1772.

42. Hertel L (2014) Human cytomegalovirus tropism for mucosal myeloid dendritic cells. *Reviews in medical virology* 24(6):379-395.

43. Hertel L, Lacaille VG, Strobl H, Mellins ED, & Mocarski ES (2003) Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. *J Virol* 77(13):7563-7574.

44. Huang MM, Kew VG, Jestice K, Wills MR, & Reeves MB (2012) Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model. *J Virol* 86(16):8507-8515.

45. Sinzger C, et al. (1999) Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. *J Gen Virol* 80 (Pt 11):2867-2877.

46. Lemmermann NA, et al. (2015) Non-redundant and redundant roles of cytomegalovirus gH/gL complexes in host organ entry and intra-tissue spread. *PLoS Pathog* 11(2):e1004640.

47. Digel M, Sampaio KL, Jahn G, & Sinzger C (2006) Evidence for direct transfer of cytoplasmic material from infected to uninfected cells during cell-associated spread of human cytomegalovirus. *J Clin Virol* 37(1):10-20.

48. Gerna G, et al. (2000) Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. *J Virol* 74(12):5629-5638.

49. Silva MC, Schroer J, & Shenk T (2005) Human cytomegalovirus cell-to-cell spread in the

absence of an essential assembly protein. *Proc Natl Acad Sci U S A* 102(6):2081-2086.

50. Gerna G, Percivalle E, Perez L, Lanzavecchia A, & Lilleri D (2016) Monoclonal antibodies to different components of the human cytomegalovirus (HCMV) pentamer gH/gL/pUL128L and trimer gH/gL/gO as well as antibodies elicited during primary HCMV infection prevent epithelial cell syncytium formation. *J Virol* 90(14):6216-6223.

51. Cui X, et al. (2017) Impact of antibodies and strain polymorphisms on cytomegalovirus entry and spread in fibroblasts and epithelial cells. *J Virol*.

52. Carr JM, Hocking H, Li P, & Burrell CJ (1999) Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. *Virology* 265(2):319-329.

53. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, & Schwartz O (2007) Inefficient human immunodeficiency virus replication in mobile lymphocytes. *J Virol* 81(2):1000-1012.

54. Chen P, Hubner W, Spinelli MA, & Chen BK (2007) Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. *J Virol* 81(22):12582-12595.

55. Richardson MW, et al. (2008) Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. *J Virol* 82(22):11117-11128.

56. Jolly C, Booth NJ, & Neil SJ (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. *J Virol* 84(23):12185-12199.

57. Vendrame D, Sourisseau M, Perrin V, Schwartz O, & Mammano F (2009) Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. *J Virol* 83(20):10527-10537.

58. Sattentau Q (2008) Avoiding the void: cell-to-cell spread of human viruses. *Nat Rev Microbiol* 6(11):815-826.

59. Mothes W, Sherer NM, Jin J, & Zhong P (2010) Virus cell-to-cell transmission. *J Virol* 84(17):8360-8368.

60. Schiffer T, Sattentau QJ, & Duncan CJ (2013) Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. *Vaccine* 31(49):5789-5797.

61. McCoy LE, et al. (2014) Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. *Retrovirology* 11:83.

62. Malbec M, et al. (2013) Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. *J Exp Med* 210(13):2813-2821.

63. Abela IA, et al. (2012) Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. *PLoS Pathog* 8(4):e1002634.

64. Martin N, et al. (2010) Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. *J Virol* 84(7):3516-3527.

65. Durham ND, et al. (2012) Neutralization resistance of virological synapse-mediated HIV-1 infection is regulated by the gp41 cytoplasmic tail. *J Virol* 86(14):7484-7495.

66. Duncan CJ, et al. (2014) High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. *J Virol* 88(4):2025-2034.

67. Reh L, et al. (2015) Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. *PLoS Pathog* 11(7):e1004966.

68. Lauron E, Yu D, Fehr AR, & Hertel L (2014) Human Cytomegalovirus Infection of Langerhans-Type Dendritic Cells Does Not Require the Presence of the gH/gL/UL128-131A Complex and Is Blocked after Nuclear Deposition of Viral Genomes in Immature Cells. *J Virol* 88(1):403-416.

69. Davis AJ, Li P, & Burrell CJ (1997) Kinetics of viral RNA synthesis following cell-to-cell transmission of human immunodeficiency virus type 1. *J Gen Virol* 78 (Pt 8):1897-1906.

70. Sato H, Orenstein J, Dimitrov D, & Martin M (1992) Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. *Virology* 186(2):712-724.

71. Del Portillo A, et al. (2011) Multiploid inheritance of HIV-1 during cell-to-cell infection. *J Virol* 85(14):7169-7176.

72. Sigal A, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. *Nature* 477(7362):95-98.

73. Dang Q, et al. (2004) Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. *Proc Natl Acad Sci U S A* 101(2):632-637.

74. Lilleri D & Gerna G (2016) Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy. *Reviews in medical virology* 27(2).

75. Lilleri D, et al. (2013) Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection. *PLoS One* 8(3):e59863.

76. Lilleri D, Kabanova A, Lanzavecchia A, & Gerna G (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. *J Clin Immunol* 32(6):1324-1331.

77. Fornara C, et al. (2015) Primary human cytomegalovirus infections: kinetics of ELISA-IgG and neutralizing antibody in pauci/asymptomatic pregnant women vs symptomatic non-pregnant subjects. *J Clin Virol* 64:45-51.

78. Wirtz N, et al. (2008) Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. *Med Microbiol Immunol* 197(2):151-158.

79. Auerbach MR, et al. (2014) A Neutralizing Anti-gH/gL Monoclonal Antibody Is Protective in the Guinea Pig Model of Congenital CMV Infection. *PLoS Pathog* 10(4):e1004060.

80. Ishida JH, et al. (2017) Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. *Antimicrob Agents Chemother* 61(2).

81. Griffiths PD, et al. (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. *Lancet* 377(9773):1256-1263.

82. Aicheler RJ, Wang ECY, Tomasec P, Wilkinson GWG, & Stanton RJ (2013) Potential for Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity for Control of Human Cytomegalovirus. *Antibodies* 2(4):617-635.

749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816